Short Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 88.0%

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) saw a large growth in short interest during the month of May. As of May 29th, there was short interest totaling 36,835 shares, a growth of 88.0% from the May 14th total of 19,598 shares. Based on an average daily volume of 59,827 shares, the days-to-cover ratio is currently 0.6 days. Approximately 0.7% of the shares of the company are sold short.

Institutional Investors Weigh In On Neuphoria Therapeutics

Several institutional investors have recently modified their holdings of the company. Geode Capital Management LLC boosted its stake in shares of Neuphoria Therapeutics by 33.3% during the 4th quarter. Geode Capital Management LLC now owns 17,303 shares of the company’s stock worth $67,000 after acquiring an additional 4,325 shares in the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Neuphoria Therapeutics during the 3rd quarter worth approximately $58,000. Commonwealth Equity Services LLC purchased a new stake in shares of Neuphoria Therapeutics during the 4th quarter worth approximately $43,000. XTX Topco Ltd purchased a new stake in shares of Neuphoria Therapeutics during the 4th quarter worth approximately $47,000. Finally, Boothbay Fund Management LLC purchased a new stake in shares of Neuphoria Therapeutics during the 4th quarter worth approximately $54,000. Hedge funds and other institutional investors own 15.90% of the company’s stock.

Neuphoria Therapeutics Price Performance

NASDAQ NEUP traded down $0.01 on Tuesday, hitting $4.28. 69,603 shares of the company’s stock were exchanged, compared to its average volume of 49,825. The firm’s 50-day moving average price is $4.92 and its two-hundred day moving average price is $4.44. Neuphoria Therapeutics has a fifty-two week low of $3.64 and a fifty-two week high of $21.40. The firm has a market cap of $23.11 million, a price-to-earnings ratio of -0.39 and a beta of 0.72.

Neuphoria Therapeutics (NASDAQ:NEUP) last announced its quarterly earnings results on Friday, May 15th. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.47. On average, research analysts predict that Neuphoria Therapeutics will post -4.07 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on NEUP shares. HC Wainwright downgraded Neuphoria Therapeutics from a “buy” rating to a “neutral” rating in a research note on Friday, May 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Neuphoria Therapeutics in a research report on Monday, June 1st. One equities research analyst has rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Neuphoria Therapeutics presently has a consensus rating of “Hold” and an average target price of $21.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.